MACCLESFIELD, England, April 21, 2010 /PRNewswire/ -- Cyprotex (AIM:CRX), the drug discovery technology and information company, is pleased to announce that it has received French research tax credit approval for years 2009 through to 2011.

The French Ministry of Research (Ministère de l'Enseignement Supérieur et de la Recherche) has granted the French RD tax credit (Crédit d'Impôt Recherche, CIR) accreditation to Cyprotex as of March 2010. This initiative allows eligible French pharmaceutical, biotech and agricultural companies subject to corporate tax in France, the ability to claim significant tax relief on costs generated in RD requirements that are outsourced to Cyprotex Discovery.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: 'We are delighted to receive this recognition and approval from the French Ministry of Research which will provide greater opportunities to support our current client base and allow for improved collaborations with future French clients.'

Additional information on the French research tax credit system is available from the Ministère de l'Enseignement Supérieur et de la Recherche site -

For further information: Cyprotex PLC Dr. Anthony Baxter, Chief Executive Officer Tel: +44-1625-505-100 Execution Noble Company Limited John Llewellyn-Lloyd Sam Reynolds Tel:+44(0)20-7456-9191 Public Relations Financial Dynamics Ben Brewerton Ben Atwell Mo Noonan Tel: +44(0)20-7831-3113

SOURCE: Cyprotex

CONTACT: For further information: Cyprotex PLC, Dr. Anthony Baxter, ChiefExecutive Officer, Tel: +44-1625-505-100,,; Execution Noble Company Limited, JohnLlewellyn-Lloyd, Sam Reynolds, Tel:+44(0)20-7456-9191; Public Relations,Financial Dynamics, Ben Brewerton, Ben Atwell, Mo Noonan, Tel:+44(0)20-7831-3113